Bayer completed the acquisition of Blackford Analysis.

Bayer, a pharmaceutical and biotechnology company, completed the acquisition of Blackford Analysis, a strategic imaging AI platform and solutions provider. Financial terms were not disclosed. “Adding Blackford and its AI technology to our radiology portfolio secures Bayer an excellent position in the fastest growing segment within the overall global radiology industry. This acquisition complements our comprehensive radiology portfolio and nourishes our engagement to drive innovation in digital health. We are pleased to join forces with Blackford and their exceptional team to optimally utilize our combined expertise in healthcare technology with the aim to deliver true value to radiologists and their teams for the benefit of their patients,” Stefan Oelrich, Bayer President of Pharmaceutical Division.